Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer

Journal of Surgical Oncology

Volumn 81, Issue 2, 2002, Pages 87-92

  Nakagawa, Tatsuo ^a   Tanaka, Fumihiro ^a   Takata, Tetsuya ^a   Matsuoka, Katsunari ^a   Miyahara, Ryo ^a   Otake, Yosuke ^a   Yanagihara, Kazuhiro ^a   Fukushimab, Masakazu ^b   Wada, Hiromi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Adjuvant chemotherapy; Dihydropyrimidine dehydrogenase; Nonsmall cell lung cancer; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; UFT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR CELL;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG COMBINATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXIDOREDUCTASES; POSTOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 0036787798     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10137     Document Type: Article

References (22)

1. Mountain CF: Value of the new TNM staging system for lung cancer. Chest 1989;96:47-49.
2. Naruke T, Goya T, Tsuchiya R, et al.: Prognosis and survival in resected on the new international staging system. J Thorac Cardiovasc Surg 1988;96:440-447.
3. Bains MS: Surgical treatment of the cancer. Chest 1991;100:826-837.
4. Langenback RJ, Danenberg PV, Heidelberger C: Thymidylate synthase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 1972;48:1565-1571.
5. Matuoka H, Ueo H, Sugimachi K, et al.: Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response. Cancer Invest 1992;10:265-269.
6. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-237.
7. Beck A, Etienne MC, Cheradame S, et al.: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 1994;30:1517-1522.
8. Kirihara Y, Yamamoto W, Toge T, et al.: Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 1999;14:551-556.
9. Ishikawa Y, Kubota T, Otani Y, et al.: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 2000;91:105-112.
10. Ishikawa Y, Kubota T, Otani Y, et al.: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 1999;5:883-889.
11. Etienne MC, Cheradame S, Fischel JL, et al.: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13:1663-1670.
12. Salonga D, Danenberg KD, Johnston M, et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-1327.
13. Huang CL, Yokomise H, Kobayashi S, et al.: Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 2000;17:47-54.
14. Wada H, Hitomi S, Teramatsu T, et al.: Adjuvant chemotherapy after complete resection in non-small lung cancer. J Clin Oncol 1996;14:1048-1054.
15. Wada H, Ryo M, Fumihiro T, et al.: Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesin + mitomycin C) and UFT (Uracil + Tegafur) in resected stage I-II NSCLC (nonsmall cell lung cancer). Eur J Cardiothorac Surg 1999;15:438-443.
16. Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan): A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol 1995;21:69-77.
17. Tanaka F, Miyahara R, Ohtake Y, et al.: Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 1998;14:256-262.
18. Moutain CF: Revisions in the international system for staging lung cancer. Chest 1997;116:1710-1717.
19. World Health Organization: Histological typing of lung tumors. Third edition. Geneva: WHO; 1999.
20. American Society of Clinical Oncology. ASCO special article. Clinical practice guidelines for the treatment of unresectable nonsmall cell lung cancer. J Clin Oncol 1997;15:2996-3018.
21. Takechi T, Okabe H, Fujioka A, et al.: Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice. Jpn J Cancer Res 1998;89:1144-1153.
22. Ho DH, Townsend L, Luna MA, et al.: Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 1986;6:781-784.